Anti-CD30 CAR T-Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
J. Clin. Oncol 2020 Jul 23;[EPub Ahead of Print], CA Ramos, NS Grover, AW Beaven, PD Lulla, MF Wu, A Ivanova, T Wang, TC Shea, CM Rooney, C Dittus, SI Park, AP Gee, PW Eldridge, KL McKay, B Mehta, CJ Cheng, FB Buchanan, BJ Grilley, K Morrison, MK Brenner, JS Serody, G Dotti, HE Heslop, B SavoldoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.